Celldex Therapeutics (CLDX) Return on Sales (2010 - 2026)

Celldex Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 57.27% for Q1 2026.

• On a quarterly basis, Return on Sales fell 5637.0% year-over-year to 57.27% in Q1 2026; TTM through Mar 2026 was 3.77%, a 311.0% decrease from a year earlier, with the FY2025 full-year figure at 4.28%, down 360.0% from the prior year.
• Return on Sales declined to 57.27% in Q1 2026 per CLDX's latest filing, from 9.06% in the prior quarter.
• Across five years, Return on Sales topped out at 0.15% in Q3 2024 and bottomed at 57.27% in Q1 2026.
• The 5-year median for Return on Sales is 0.95% (2023), against an average of 4.9%.
• Across the five-year window, Return on Sales jumped 181 bps in 2025 and tumbled 5637 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.16% in 2022, then sank by 476 bps to 0.95% in 2023, then slumped by 206 bps to 2.9% in 2024, then tumbled by 213 bps to 9.06% in 2025, then sank by 532 bps to 57.27% in 2026.
• Per Business Quant, the three latest CLDX Return on Sales figures stand at 57.27% (Q1 2026), 9.06% (Q4 2025), and 2.06% (Q3 2025).